SPACs remain in the SEC’s crosshairs with this comprehensive rule proposal that expands the scope of underwriter liability, amends the scope of a safe harbor for financial projections a...
Updated September 3, 2021Recently a purported shareholder of certain SPACs initiated derivative lawsuits asserting that the SPACs are investment companies under the Investment Company Act...
The SEC continued its recent focus on SPACs by filing charges against both sides of a planned but not yet completed SPAC merger, including charges against the SPAC and its CEO for adoptin...
This week, the staff of the SEC issued a statement expressing a view that, despite the widespread practice to the contrary, most warrants issued in connection with a SPAC transaction shou...
In light of the many questions our clients have been asking about the legal implications of the coronavirus (COVID-19) crisis and government responses to the pandemic, Davis Polk this wee...
With recent increased activity in the area of sovereign bond offerings (including a rise in issuances of “green bonds”) and liability management transactions, we thought it timely to ...
The first quarter of 2018 saw continued significant securities-suit filing activity against life sciences companies with more than 10 actions filed, including several filed by some of the...
As part of a series of regular updates on developments in life sciences securities litigation (see Q3 2017 Quarterly Report), this report addresses recent activity in securities actions a...
We previously highlighted the increased activity and some emerging patterns in securities litigation against life sciences companies during the first half of 2017. This report, the first...
We
previously outlined the growing threat of securities class action lawsuits against life sciences companies and the importance of the United States Supreme Court’s decision in Omnic...
